Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 6Neuroendocrine Tumors 2Urogenital Neoplasms 1Prostatic Diseases 1Oligometastatic Prostate Cancer (OMPC) 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Carcinoma, Merkel Cell 1Carcinoma 1Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

darolutamide 2olaparib 1gedatolisib 1gallium 68 PSMA-11 1Radiotherapy 1Pluvicto 1Nivolumab 1Lutetium-177 1Lutetium 1Cryotherapy 1Brachytherapy 1Androgen Antagonists 1Abiraterone Acetate 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Diseases × Lutetium-177 × 90 days × Clear all
NCT05413850 2026-05-14

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Blue Earth Therapeutics Ltd

Phase 1/2 Recruiting
82 enrolled
Genitourinary

Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡